Results: The CT values in the central and zones of 2, 6 and 10 mm on day 3 after treatment were statistically significantly thicker when compared to baseline and controls (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Purpose: The aim of this study was to evaluate the effects of topical 0.1% brimonidine on the corneal densitometry.
📊
Key Findings & Data:Materials and Methods: This prospective study included 32 eyes of 17 patients who were diagnosed with primary open angle glaucoma and treated with 0.1% brimonidine, and 28 eyes of 14 healthy individuals.
💡
Conclusion & Impact:Results: The CT values in the central and zones of 2, 6 and 10 mm on day 3 after treatment were statistically significantly thicker when compared to baseline and controls (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Purpose: The aim of this study was to evaluate the effects of topical 0.1% brimonidine on the corneal densitometry. Materials and Methods: This prospective study included 32 eyes of 17 patients who were diagnosed with primary open angle glaucoma and treated with 0.1% brimonidine, and 28 eyes of 14 healthy individuals. Corneal densitometry and corneal thickness (CT) were evaluated in the three corneal zones (0-2, 2-6, 6-10) by Scheimpflug corneal topography at baseline and on day 3, 17 and 30 after the treatment. Results: The CT values in the central and zones of 2, 6 and 10 mm on day 3 after treatment were statistically significantly thicker when compared to baseline and controls (p
🔖
Cite This Article
IRGAT, S. G., ÖZCURA, F., ALTUNEL, O. (2022). Evaluation of Corneal Transparency in Eyes Treated with Brimonidine. Glokom Katarakt, Cilt: 16 - Sayı: 3, 131–137. https://ajindex.com/articles/525739
Fudemberg, S.J., Batiste, C., Katz, L.J. Efficacy, safety, and current applications of brimonidine. Expert Opin. Drug Saf. 2008;7:975-9
Reitsamer H.A., Posey M., Kiel J.W. Effects of a topical alpha2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits. Exp. Eye Res. 2006;82:405-15
Kalapesi F.B., Coroneo M.T., Hill M.A. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br. J. Ophthalmol. 2005;89:758-63
Matthias G., Joerg M., Jens Martin R., et al. Effect of brimonidine on corneal thickness. 2011;27:503-9 5. Ozyol P, Ozyol E. Assessment of corneal backward light scattering in diabetic patients. Eye Contact Lens. 2018;44:92-6
Ni Dhubhghaill S, Rozema JJ, Jongenelen S, et al. Normative values for corneal densitometry analysis by Scheimpflug optical assessment. Invest Ophthalmol Vis Sci 2014;55:162-8
Lopes B, Ramos I, Ambrósio R Jr. Corneal densitometry in keratoconus. Cornea. 2014;33:1282-6
Oliveira CM, Ribeiro C, Franco S. Corneal imaging with slit- scanning and Scheimpflug imaging techniques. Clin Exp Optom. 2011;94:33-42
Becquet F, Goldschild M, Moldovan MS, et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998;17:419-25
Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490- 6
Hamard P, Debbasch C, Blondin C, et al. Human trabecular cells and apoptosis: in vitro evaluation of the effect of betaxolol with or without preservative. J Fr Ophthalmol. 2002;25:777-84
Osborne SA, Montgomery DM, Morris D, et al. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye (Lond). 2005;19:129-37
Manni G, Centofanti M, Sacchetti M, et al. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%- induced ocular allergy. J Glaucoma. 2004;13:163- 7
Manabe Y, Sawada A, Mochizuki K. Corneal sterile infiltration induced by topical use of ocular hypotensive agent. European Journal of Ophthalmology. 2020;30:23-5
Tsujinaka A, Takai Y, Inoue Y, et al. A case of bilateral deep stromal corneal opacity and vascularization after use of multiple antiglaucoma medications including brimonidine tartrate ophthalmic solution. Acta Ophthalmologica, 2019;97:948-9
Maruyama Y, Ikeda Y, Yokoi N et al. Severe corneal disorders developed after brimonidine tartrate